Molecular Determinants of the Cytotoxicity of Platinum Compounds

Gene expression profiling of tumors allows the establishment of relationships between gene expression profiles and sensitivity to anticancer drugs. In an attempt to study the molecular determinants of the activity of platinum compounds, we explored the publicly available databases of the National Cancer Institute (NCI; http://dtp.nci.nih.gov), which allow access to the gene expression profiles of the 60 cell lines for which drug cytotoxicity patterns already existed. Using this database, we have conducted an in silico research to identify the genes the expression of which was positively or negatively correlated to the sensitivity to four platinum compounds (cisplatin, carboplatin, oxaliplatin and tetraplatin). Important similarities were noticed between cisplatin and carboplatin on one hand, and tetraplatin and oxaliplatin on the other hand. In the restricted panel of 1416 genes and molecular markers, we identified 204 markers, among which 120 corresponded to identified genes, that significantly correlated (P < 0.001) with the cytotoxicity of at least one platinum compound. For example, the functionality of the p53-activated pathway appeared positively correlated with the cytotoxicity of all platinum compounds. More specific are the positive correlations between RAS gene mutations and MYC expression and the cellular sensitivity to oxaliplatin. Among the parameters already known as related to the sensitivity to platinum compounds, we identified, in the complete set of 9400 genes, numerous significant relationships, such as the negative correlations between ERB-B2 and BCL-XL expressions and the cytotoxicity of the platinum compounds. Public databases mining, therefore, appears to be a valuable tool for the identification of determinants of anticancer drug activity in tumors.

[1]  J. Mesirov,et al.  Chemosensitivity prediction by transcriptional profiling , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[2]  X. Lin,et al.  Identification of genes that mediate sensitivity to cisplatin. , 2001, Molecular pharmacology.

[3]  D. Lebwohl,et al.  Clinical development of platinum complexes in cancer therapy: an historical perspective and an update. , 1998, European journal of cancer.

[4]  D. Kerr,et al.  Induction of the c-myc but not the cH-ras promoter by platinum compounds. , 1995, Biochemical pharmacology.

[5]  M. Sklar.  Increased resistance to cis-diamminedichloroplatinum(II) in NIH 3T3 cells transformed by ras oncogenes. , 1988, Cancer research.

[6]  Anders Wallqvist,et al.  Establishing connections between microarray expression data and chemotherapeutic cancer pharmacology. , 2002, Molecular cancer therapeutics.

[7]  G. Singh,et al.  Influence of the proto-oncogene c-fos on cisplatin sensitivity. , 2000, Biochemical pharmacology.

[8]  S. Aebi,et al.  The role of DNA mismatch repair in platinum drug resistance. , 1996, Cancer research.

[9]  Yusuke Nakamura,et al.  An integrated database of chemosensitivity to 55 anticancer drugs and gene expression profiles of 39 human cancer cell lines. , 2002, Cancer research.

[10]  S. Hector,et al.  In vitro studies on the mechanisms of oxaliplatin resistance , 2001, Cancer Chemotherapy and Pharmacology.

[11]  J. Brown,et al.  NCI's anticancer drug screening program may not be selecting for clinically active compounds. , 1997, Oncology research.

[12]  S. Groshen,et al.  ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  R. Golbey,et al.  High dose Cis‐platinum diammine dichloride. Amelioration of renal toxicity by mannitol diuresis , 1977, Cancer.

[14]  M. Widschwendter,et al.  Cisplatin resistance is associated with reduced interferon-gamma-sensitivity and increased HER-2 expression in cultured ovarian carcinoma cells. , 1997, British Journal of Cancer.

[15]  S. Guichard,et al.  Cellular determinants of oxaliplatin sensitivity in colon cancer cell lines. , 2003, European journal of cancer.

[16]  J C Reed,et al.  Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. , 1996, Cancer research.

[17]  E. Raymond,et al.  Cellular and molecular pharmacology of oxaliplatin. , 2002, Molecular cancer therapeutics.

[18]  K. Paull,et al.  Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. , 1996, Biochemical pharmacology.

[19]  B. Rosenberg.  Fundamental studies with cisplatin. , 1985, Cancer.

[20]  I. Weinstein.  Addiction to Oncogenes--the Achilles Heal of Cancer , 2002, Science.

[21]  Y. Terashima,et al.  [Resistance to anticancer drugs in NIH3T3 cells transfected with c-myc and/or c-H-ras genes]. , 1990, Human Cell.

[22]  D. Hamer,et al.  Overexpression of metallothionein confers resistance to anticancer drugs. , 1988, Science.

[23]  J. Misset,et al.  Oxaliplatin clinical activity: a review. , 2000, Critical reviews in oncology/hematology.

[24]  B. Wouters,et al.  Apoptosis, p53, and tumor cell sensitivity to anticancer agents. , 1999, Cancer research.

[25]  Yusuke Nakamura,et al.  Genome-wide cDNA microarray screening to correlate gene expression profiles with sensitivity of 85 human cancer xenografts to anticancer drugs. , 2002, Cancer research.

[26]  J. Lokich,et al.  Carboplatin versus cisplatin in solid tumors: an analysis of the literature. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[27]  A. Godwin,et al.  High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[28]  J N Weinstein,et al.  Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. , 1997, Cancer research.

[29]  D. Botstein,et al.  A gene expression database for the molecular pharmacology of cancer , 2000, Nature Genetics.

[30]  G. Wilding,et al.  Phase I clinical and pharmacokinetic study of an one-hour infusion of ormaplatin (NSC 363812) , 2004, Investigational New Drugs.

[31]  G. Samimi,et al.  The cellular pharmacology of oxaliplatin resistance. , 2002, European journal of cancer.

[32]  J C Reed,et al.  The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and Bcl-2. , 1995, Oncogene.

[33]  Barnett Rosenberg,et al.  Charles F. Kettring prize. Fundamental studies with cisplatin , 1985 .

[34]  R. Ozols,et al.  Platinum analogues in preclinical and clinical development , 1993, Current opinion in oncology.

[35]  M. Shibuya,et al.  Resistance to anticancer drugs in NIH3T3 cells transfected with c-myc and/or c-H-ras genes. , 1991, British Journal of Cancer.

[36]  H. Miyake,et al.  Overexpression of Bcl-2 in bladder cancer cells inhibits apoptosis induced by cisplatin and adenoviral-mediated p53 gene transfer , 1998, Oncogene.

[37]  W G Alvord,et al.  Enhanced sensitivity to 1-beta-D-arabinofuranosylcytosine and topoisomerase II inhibitors in tumor cell lines harboring activated ras oncogenes. , 1996, Cancer research.

[38]  N. Saijo,et al.  An active efflux system for heavy metals in cisplatin-resistant human KB carcinoma cells. , 1998, Experimental cell research.

[39]  R. Perez,et al.  Cellular and molecular determinants of cisplatin resistance. , 1998, European journal of cancer.

[40]  D. Scudiero,et al.  Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. , 1991, Journal of the National Cancer Institute.